Pfizer facing challenges with declining revenue, earnings, and stock price, impacted by regulatory changes

From Nasdaq: 2025-06-01 09:15:00

Pfizer has faced challenges over the past three years, with revenue, earnings, and stock price all declining. Recent regulatory changes in the U.S. will impact the company’s ability to generate revenue from its COVID-19 vaccine, Comirnaty. Despite this, Pfizer’s overall revenue increased by 7% to $63.6 billion in 2024, with $11.1 billion coming from its coronavirus products. The company’s focus on oncology and other therapies may help offset any potential losses from the vaccine market. Investors should consider Pfizer’s long-term prospects and strategic investments in its pipeline for potential returns.



Read more at Nasdaq: Terrible News for Pfizer Stock Investors